Aditum Bio
VC Fund
San Francisco, United States
Aditum Bio is an investment fund that specializes in acquiring and developing pharmaceutical assets. It gives patients access to medicines that may not otherwise be developed. Aditum Bio was founded on 2019 and is headquartered in San Francisco, California.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 17%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Aditum Bio invests in
Stages Aditum Bio invests in
Countries Aditum Bio invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
1 more contact available
Round size
- Series A
- $20M–$70M
- Series B
- $62M–$77M
Investment Focus
Industry
- Biotechnology 4 (67%)
- Biopharma 2 (33%)
- Life Science 2 (33%)
- Therapeutics 2 (33%)
- FinTech 1 (17%)
Stage
- Series A 3 (50%)
- Series B 2 (33%)
- Pre-Seed 1 (17%)
Country
- United States 4 (67%)
- United Arab Emirates 2 (33%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Joe Jimenez
Co-Founder and Managing Director
|
Co-Founder and Managing Director | Total investments: 2 | Find email | |
Ilan Zipkin
Partner and VP, Business Development and Licensing
|
Partner and VP, Business Development and Licensing | Total investments: 5 | Find email | |
|
Mark Fishman
Co-Founder and Chair of the Scientific Advisory BoardAditum Bio
|
Co-Founder and Chair of the Scientific Advisory BoardAditum Bio | Total investments: 0 | Find email | |
Susie Phillips
Executive Assistant to Co-Founder and Managing Director
|
Executive Assistant to Co-Founder and Managing Director | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Oblenio Bio
|
Oblenio Bio is a biotechnology company that develops T-cell engager therapeutic candidates for autoimmune disease treatment. | $62M / Series B / Jun 25, 2026 | |
Tempero Bio
|
Tempero Bio develops treatments for Substance Use Disorders as a clinical-stage biopharmaceutical company. | $77M / Series B / Mar 24, 2025 | |
Qeen Ai
|
qeen.ai is a GenAI native platform that enables autonomous AI to e-commerce firms of all sizes. | $2.2M / Pre-Seed / Jun 05, 2024 | |
Hubpay
|
Hubpay is an independently regulated provider of cross-border money services designed to increase financial inclusion in emerging markets. | $20M / Series A / Feb 08, 2022 | |
Via Nova Therapeutics
|
Via Nova Therapeutics is to discover and develop therapeutics for acute and subacute viral infections for which current treatments are lacking or inadequate. The current programs were part of an antiviral portfolio led by the founders while at Novartis and target several important respiratory viruses (including influenza viruses, adenoviruses, andrhinoviruses) as well as human polyomaviruses, which produce severe disease in immunocompromised hosts. The company targets fundamental mechanisms of viral replication and accordingly can support discovery of novel therapeutics for other viral infections as well. | $20M / Series A / Sep 07, 2021 | |
Versanis Bio
|
Versanis Bio is advancing bimagrumab, a human monoclonal antibody to the activin type II receptors that blocks the binding of ligands including activin A and myostatin. Bimagrumab has been studied by Novartis in more than a dozen controlled clinical trials that enrolled more than 1,500 people. Across key studies bimagrumab treatment consistentlyand potently induced significant loss of fat mass without loss of lean mass, and additionally improved HbA1c and other cardiometabolic parameters. | $70M / Series A / Aug 31, 2021 |
Co-Investors
Deep Track Capital
2 deals together
10x Founders
1 deal together
8VC
1 deal together
Aditum Ventures
1 deal together
Atlas Venture
1 deal together
BECO Capital
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Aditum Bio invest in?
Aditum Bio invests primarily in Biotechnology, Biopharma and Life Science startups, most often at Series A and Series B stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Aditum Bio's check size?
Aditum Bio typically joins rounds of $20M–$70M at Series A and $62M–$77M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Aditum Bio participates in.
How do I contact Aditum Bio?
Public channels for Aditum Bio include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Aditum Bio?
The team at Aditum Bio includes Joe Jimenez (Co-Founder and Managing Director), Ilan Zipkin (Partner and VP, Business Development and Licensing) and Mark Fishman (Co-Founder and Chair of the Scientific Advisory BoardAditum Bio). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
